Is Coeptis Therapeutics Holdings Inc (COEP) Stock About to Get Hot Tuesday?

Overall market sentiment has been high on Coeptis Therapeutics Holdings Inc (COEP) stock lately. COEP receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Coeptis Therapeutics Holdings Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on COEP!

See Full COEP Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With COEP Stock Today?

Coeptis Therapeutics Holdings Inc (COEP) stock is down -10.09% while the S&P 500 is higher by 0.26% as of 12:49 PM on Tuesday, Oct 31. COEP is lower by -$0.13 from the previous closing price of $1.34 on volume of 64,403 shares. Over the past year the S&P 500 is up 7.90% while COEP is lower by -81.54%. COEP lost -$3.47 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Coeptis Therapeutics Holdings Inc click here.

More About Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania. Click Here to get the full Stock Report for Coeptis Therapeutics Holdings Inc stock.